menu
    • menu
    [{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cartography Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartography Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Cartography Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"CBI-1214","moa":"CD3\/LY6G6D","graph1":"Oncology","graph2":"Phase I","graph3":"Cartography Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Cartography Biosciences \/ Pfizer Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Cartography Biosciences \/ Pfizer Ventures"},{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CBI-1214","moa":"CD3\/LY6G6D","graph1":"Oncology","graph2":"Phase I","graph3":"Cartography Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartography Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cartography Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2026","type":"Inapplicable","leadProduct":"CBI-1214","moa":"CD3\/LY6G6D","graph1":"Oncology","graph2":"Phase I","graph3":"Cartography Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartography Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cartography Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2026","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Cartography Biosciences","amount2":0.84999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Cartography Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Cartography Biosciences \/ Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Cartography Biosciences

    Menu

    Cartography Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBI-1214

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell ...

                            Details : CBI-1214 is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 06, 2026

                            Lead Product(s) : CBI-1214

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : $850.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cartography Biosciences, Pfizer Collaborate on Tumor-Selective Antigens Discovery

                            Details : The collaboration aims to advance cancer research with an undisclosed lead product in the oncology space.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $65.0 million

                            January 06, 2026

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : $850.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBI-1214

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cartography Gets FDA IND Approval, Fast Track for CBI-1214 in Colorectal Cancer

                            Details : CBI-1214, an unconjugated antibody targeting CD3/LY6G6D, shows promise in treating colorectal cancer (CRC).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 18, 2025

                            Lead Product(s) : CBI-1214

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBI-1214

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Pfizer Ventures

                            Deal Size : $67.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cartography Raises $67M to Advance Oncology Antibody Pipeline.

                            Details : The Series B financing will support the development of T-cell engaging bispecific and multi-specific antibody therapeutics targeting novel tumor antigens in oncology.

                            Product Name : CBI-1214

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 02, 2025

                            Lead Product(s) : CBI-1214

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Pfizer Ventures

                            Deal Size : $67.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Cartography Biosciences

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cartography Announces Collaboration with Gilead for Oncology Therapies

                            Details : The collaboration aims to support the discovery and development of therapies for patients with triple-negative breast cancer and the most common form of non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $20.0 million

                            May 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.